Merck has cut the price of its diabetes drug Januvia by 42%, aiming to align list prices with net prices and responding to changes in the Medicaid rebate program. Meanwhile, Neumora's experimental depression drug failed in a Phase 3 study, causing an 83% drop in its stock. Roche is expanding its presence in the antibody-drug conjugate space through a deal with Innovent Biologics, which could yield up to $1 billion in milestone payments.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.